The global prazosin market is estimated to exhibit a negative CAGR of around 2% during the forecast period. Though the rise in CVDs due to high BP, increasing patient pool, and increasing awareness toward mental care are some of the positive factors for the growth of the market. However, due to the presence of alternative drugs, discontinuation of prazosin manufacturing by companies in the last decade, unfavorable reimbursement policies for the branded drug in medical insurance, and side effects associated with the drugs, the market is expected to show a negative growth rate during the forecast period.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/prazosin-market
The global prazosin market is segmented on the basis of its application into cardiovascular disease, neurological syndromes, prostate disorders, and kidney disorders. It is majorly used for cardiovascular disease that is used to relieve hypertension/high BP due to which it will hold the largest market share.
Geographically, the study of the global prazosin market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World. North America is expected to hold the largest market share during the forecast period. The high cost of drugs, significant sale of branded drugs of Pfizer in the region is major factors for the largest market, globally. In October 2018, Novitium Pharma LLC received the US FDA approval for its Prazosin Hydrochloride Capsules USP which is also providing significant market share in the region.
The companies which are contributing to the growth of the global prazosin market include Pfizer Inc., Mylan N.V., Merk KGaA, Teva Pharmaceuticals Industries Ltd., Apotex Inc., and others. The market players are considerably contributing to the market growth by adopting various strategies including new product launch, merger, and acquisition to stay competitive in the market. In November 2019, Pfizer Inc., and Mylan NV announced to form a new company named Viatris by merging Mylan and Upjohn division of Pfizer. The deals were expected to be closed by mid of 2020, however, due to the COVID-19 pandemic, the deal is expected to close by the end of 2020.
Global Prazosin Market- Segmentation
By Application
- Cardiovascular Disease(CVD)
- Neurological Syndromes
- Prostate Disorders
- Kidney Disorders
A full report of Global Prazosin Market is available at: https://www.omrglobal.com/industry-reports/prazosin-market
